MicroRNA-214 targets COX-2 to antagonize indoxyl sulfate (IS)-induced endothelial cell apoptosis
Related Experiment Video
Updated: Jan 2, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Shuzhen Li1,2,3, Yifan Xie1,2,3, Bingyu Yang1,2,3
1Department of Nephrology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing, 210008, People's Republic of China.
Insights
MicroRNA-214 protects against indoxyl sulfate-induced endothelial cell apoptosis in chronic kidney disease. It achieves this by downregulating the COX-2/PGE2 pathway, offering a potential therapeutic target for cardiovascular disease.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Nephrology
Background:
- Cardiovascular disease (CVD) is the leading cause of death in chronic kidney disease (CKD) patients.
- Uremic toxins, such as indoxyl sulfate (IS), contribute to endothelial injury and CVD pathogenesis in CKD.
- The precise mechanisms by which IS induces endothelial damage remain incompletely understood.
Purpose of the Study:
- To investigate the role of microRNA-214 (miR-214) in indoxyl sulfate (IS)-induced endothelial cell apoptosis.
- To elucidate the underlying molecular mechanisms of miR-214 in IS-mediated endothelial injury.
Main Methods:
- Mouse aortic endothelial cells (MAECs) were treated with IS.
- miR-214 levels, cell apoptosis, COX-2 expression, and PGE2 secretion were measured.
- miR-214 levels were modulated (overexpression and antagonism) to assess its functional role.
- The effect of COX-2 inhibition on IS-induced apoptosis was evaluated.
Main Results:
- IS treatment significantly downregulated miR-214 and induced apoptosis in MAECs.
- IS upregulated COX-2 expression and increased PGE2 secretion.
- Overexpression of miR-214 attenuated IS-induced apoptosis, while miR-214 antagonism exacerbated it.
- COX-2 was identified as a direct target of miR-214.
- Inhibition of COX-2 significantly reduced IS-induced endothelial cell apoptosis and PGE2 secretion.
Conclusions:
- miR-214 plays a protective role against IS-induced endothelial cell apoptosis.
- This protective effect is mediated through the direct downregulation of the COX-2/PGE2 axis.
- Targeting the miR-214/COX-2/PGE2 pathway may represent a novel therapeutic strategy for CVD in CKD patients.
Abstract:
Cardiovascular disease (CVD) serves as the major cause of mortality in chronic kidney disease (CKD) patients. The injury of endothelium associated with the long-term challenge of uremic toxins including the toxic indoxyl sulfate (IS) is one of key pathological factors leading to CVD. However, the mechanisms of uremic toxins, especially the IS, resulting in endothelial injury, remain unclear. miR-214 was reported to contribute to the pathogenesis of cardiovascular diseases, while its role in IS-induced endothelial cell apoptosis is unknown. In this study, we investigated the role of microRNA-214 (miR-214) in IS-induced endothelial cell apoptosis and the underlying mechanisms using mouse aortic endothelial cells (MAECs). Following IS treatment, miR-214 was significantly downregulated in MAECs in line with enhanced cell apoptosis. Meanwhile, COX-2 was upregulated at both mRNA and protein levels along with increased secretion of PGE2 in medium. To define the role of miR-214 in IS-induced endothelial cell apoptosis, we modulated miR-214 level in MAECs and found that overexpression of miR-214 markedly attenuated endothelial cell apoptosis, while antagonism of miR-214 deteriorated cell death after IS challenge. Further analyses confirmed that COX-2 is a target gene of miR-214, and the inhibition of COX-2 by a specific COX-2 inhibitor NS-398 strikingly attenuated IS-induced endothelial cell apoptosis along with a significant blockade of PGE2 secretion. In conclusion, this study demonstrated an important role of miR-214 in protecting against endothelial cell damage induced by IS possibly by direct downregulation of COX-2/PGE2 axis.
Related Concept Videos
MicroRNAs
MicroRNAs
The Intrinsic Apoptotic Pathway
Experimental RNAi

